Clinical Trials Sponsored by INSYS Therapeutics Inc

Total 2992 results

Aminex Therapeutics, Inc.

Completed

Oral AMXT 1501 Dicaprate in Combination With DFMO

Cancer | Solid Tumor | Advanced Cancer | Solid Carcinoma

United States
BioXcel Therapeutics Inc

Active, not recruiting

A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.

Prostate Cancer | Neuroendocrine Tumors | Small Cell Carcinoma

United States, United Kingdom
Mirati Therapeutics Inc.

Approved for marketing

Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation

Metastatic Cancer | Advanced Cancer | Malignant Neoplasm

United States
Vigeo Therapeutics, Inc.

Active, not recruiting

Phase 1 Study Evaluating VT1021 in Patients With Advanced Solid Tumors

Solid Tumor

United States
OcuTerra Therapeutics, Inc.

Completed

Safety and Exploratory Efficacy Study of SF0166 for the Treatment of Diabetic Macular Edema (DME)

Diabetic Macular Edema

United States
Innovo Therapeutics, Inc.

Completed

First in Human, Single Ascending Dose Study

Ulcerative Colitis

Korea, Republic of
Sorrento Therapeutics, Inc.

Withdrawn

A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies

Diffuse Large B Cell Lymphoma | Biliary Tract Cancer | Peripheral T Cell Lymphoma | Extranodal NK T Cell Lymphoma, Nasal
Click Therapeutics, Inc.

Completed

Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMo™ Component Training

Rheumatoid Arthritis | Irritable Bowel Syndrome | Fibromyalgia | Diabetic Neuropathy

United States
Click Therapeutics, Inc.

Completed

Effects of a CT-100 DiNaMo Component on Cognitive Functioning and Mood Symptoms

Multiple Sclerosis | Cancer | Mild Cognitive Impairment

United States
Protagonist Therapeutics, Inc.

Completed

PN-943 in Adults With Moderate to Severe Active Ulcerative Colitis (UC)

Ulcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic Severe

United States, Austria, Bulgaria, Canada, Georgia, Germany, Hungary, Italy, Korea, Republic of, Poland, Russian Federation, Serbia, Ukraine
Akero Therapeutics, Inc

Active, not recruiting

A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)

NASH - Nonalcoholic Steatohepatitis

United States, Mexico, Puerto Rico
Onconic Therapeutics Inc.

Completed

Clinical Trial to Evaluate the Safety and Pharmacokinetics of JP-1366 in Healthy Adult Volunteers

Healthy

Korea, Republic of
Lisata Therapeutics, Inc.

Completed

CLBS201 in Patients With Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM)

Chronic Kidney Diseases

United States
Edgewise Therapeutics, Inc.

Completed

Absorption, Metabolism, Excretion and Absolute Bioavailability of EDG-5506 in Healthy Volunteers

Nervous System Diseases | Genetic Diseases, Inborn | Musculoskeletal Diseases | Muscular Diseases | Neuromuscular Diseases | Muscular Dystrophies | Muscular Disorders, Atrophic | Healthy Volunteer

United States
Sigilon Therapeutics, Inc.

Withdrawn

Safety and Efficacy of Encapsulated Allogeneic MPS-1 Therapy

MPS I | MPS1-S | MPS1-HS

Brazil, United Kingdom
Arcturus Therapeutics, Inc.

Active, not recruiting

Phase 1b Study to Assess Safety, Tolerability, and Pharmacokinetics of ARCT-810 in Stable Adult Subjects With Ornithine Transcarbamylase Deficiency

Ornithine Transcarbamylase Deficiency

United States
Acer Therapeutics Inc.

Completed

Dose-ranging, PK, Safety, Efficacy Study of Osanetant in Patients With Moderate/Severe VMS Associated With Menopause

Post-menopausal Vasomotor Symptoms

United States
Aclaris Therapeutics, Inc.

Completed

Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA

Rheumatoid Arthritis

United States
Repurposed Therapeutics, Inc.

Completed

Efficacy and Safety of DPI-386 Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion

Motion Sickness

United States
Stemline Therapeutics, Inc.

Completed

Tagraxofusp (SL-401) in Patients With CMML or MF

Myelofibrosis | Chronic Myelomonocytic Leukemia

United States, Canada
Axsome Therapeutics, Inc.

Completed

Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)

Major Depressive Disorder | Treatment Resistant Depression

United States
Transposon Therapeutics, Inc.

Active, not recruiting

A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD

Amyotrophic Lateral Sclerosis | Frontotemporal Dementia

Spain, United States, Belgium, France, Germany
Talaris Therapeutics Inc.

Terminated

A Safety and Efficacy Study of FCR001 vs Standard of Care in de Novo Living Donor Kidney Transplantation (FREEDOM-1)

Transplanted Organ Rejection

United States
Talaris Therapeutics Inc.

Withdrawn

A Safety and Efficacy Study of FCR001 Cell Therapy in Previously Transplanted Living Donor Kidney Recipients (FREEDOM-2)

Kidney Transplantation

United States
Aldeyra Therapeutics, Inc.

Completed

The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease

Dry Eye

United States
Ashvattha Therapeutics, Inc.

Terminated

A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients (PRANA)

COVID-19

United States
Magenta Therapeutics, Inc.

Terminated

Study of MGTA-117 in Patients With Adult Acute Myeloid Leukemia (AML) and Myelodysplasia-Excess Blasts (MDS-EB)

Acute Myeloid Leukemia | Myelodysplasia

United States
Zydus Therapeutics Inc.

Suspended

Evaluate the Safety and Efficacy of Saroglitazar Mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL

Dyslipidemias

United States
Sorrento Therapeutics, Inc.

Terminated

Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (UK)

Covid19

United Kingdom
Karyopharm Therapeutics Inc

Completed

Selinexor Treatment of Refractory Myeloma (STORM)

Multiple Myeloma

United States, Belgium, Austria, France, Germany, Greece
Karyopharm Therapeutics Inc

Completed

Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies (SIGN)

Cervical Carcinoma | Endometrial Carcinoma | Ovarian Carcinoma

Denmark, Belgium
Karyopharm Therapeutics Inc

Completed

Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer

Hematological Malignancies

United States, Denmark, Canada
Karyopharm Therapeutics Inc

Terminated

Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation (SIRRT)

Richter's Transformation

United States, Germany, United Kingdom, Spain, Poland
Karyopharm Therapeutics Inc

Withdrawn

Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients (SIER)

Myelodysplastic Syndrome
Sorrento Therapeutics, Inc.

Enrolling by invitation

Long-Term Follow-Up of Patients Who Received Gene-Modified Cell Therapy

Long-term Follow-up

United States
Karyopharm Therapeutics Inc

Withdrawn

Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19

Coronavirus Infection
Karyopharm Therapeutics Inc

Withdrawn

Study of Safety, Tolerability, and Pharmacokinetics of Topical Selinexor (KPT-330) Diabetic Foot Ulcer (DFU) Patients

Diabetic Foot Ulcers

New Zealand
Karyopharm Therapeutics Inc

Terminated

Trial of Safety and Tolerability of Oral Verdinexor (KPT-335) in Healthy Adults

Healthy

Australia
Xalud Therapeutics, Inc.

Completed

Efficacy and Safety of XT-150 in Osteoarthritis of the Knee

Osteoarthritis, Knee

Australia, United States
Aldeyra Therapeutics, Inc.

Completed

A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of Subjects With Mild Asthma Induced by the Bronchial Allergen Challenge (BAC)

Atopic Asthma

Canada
Cidara Therapeutics Inc.

Completed

Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis (ReSTORE)

Mycoses | Candidemia | Fungal Infection | Invasive Candidiases

United States, Israel, Spain, Korea, Republic of, Taiwan, Singapore, Thailand, Australia, China, Turkey, Belgium, Germany, France, Argentina, Bulgaria, Colombia, Greece, Italy
Cardiol Therapeutics Inc.

Terminated

Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors

Cardiovascular Diseases | COVID-19 | Cardiovascular Risk Factor

United States, Brazil, Mexico
Applied Therapeutics, Inc.

Active, not recruiting

Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy

Diabetic Cardiomyopathies

United States, France, Spain, Australia, Canada, United Kingdom, Germany, Czechia, Hong Kong, Poland
Abeona Therapeutics, Inc

Completed

Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Epidermolysis Bullosa | Recessive Dystrophic Epidermolysis Bullosa

United States
TG Therapeutics, Inc.

Completed

Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

B-cell Lymphoma | Marginal Zone Lymphoma | Primary Central Nervous System Lymphoma | Waldenstrom's Macroglobulinemia | Non-Hodgkins Lymphoma | Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL)

United States
Antios Therapeutics, Inc

Terminated

Ethnobridging Study in Healthy Volunteers, Chinese and Japanese Subjects

Chronic Hepatitis b

United States
Samus Therapeutics, Inc.

Terminated

Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib

Primary Myelofibrosis (PMF) | Post-Polycythemia Vera Myelofibrosis (Post-PV MF) | Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)

United States
Samus Therapeutics, Inc.

Withdrawn

Evaluate PU-AD in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis (ALS)
Lisata Therapeutics, Inc.

Completed

Study to Assess the Efficacy and Safety of CLBS12 in Patients With Critical Limb Ischemia (CLI)

Critical Limb Ischemia | Thromboangiitis Obliterans | Buerger Disease | Atherosclerosis Obliterans

Japan
Kymera Therapeutics, Inc.

Completed

A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)

Atopic Dermatitis | Healthy Volunteer | Hidradenitis Suppurativa

United States

Clinical Trials Sponsored by INSYS Therapeutics Inc

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ukraine

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations